Business News • PR NewsWire • Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association

COPENHAGEN, Denmark, June 11, 2016 /PRNewswire/ -- Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21st Congress of the European Hematology Association (EHA) taking place in Copenhagen, Denmark, June 9-12, 2016, evaluating vadastuximab talirine (SGN-CD33A; 33A) in...

View More : http://www.prnewswire.com/news-releases/seattle-genetics-highlights-vadastuximab-talirine-sgn-cd33a-data-in-acute-myeloi...

Releted News by prnewswire

Home Use of a Dual Hormone, Bionic Pancreas Safely Reduces Blood Glucose Levels and Hypoglycemia in Adults While Continuing Normal Daily Activities

Janssen Presents New Data Showing INVOKANA® (canagliflozin) is Associated with Greater Blood Glucose Control and Treatment Adherence Compared to DPP-4 Inhibitors

Ronald McDonald House Charities® Of Southern California Awards 94 Scholarships To Deserving High School Seniors